论文部分内容阅读
目的探讨奥沙利铂联合替吉奥胶囊治疗晚期胃癌临床的疗效与安全性。方法对2010年6月—2012年6月郑州人民医院收治的60例晚期胃癌患者进行观察分析,随机分成两组,观察组30例采用奥沙利铂联合替吉奥胶囊治疗,对照组30例采用顺铂加5氟尿嘧啶加甲酰四氢叶酸治疗。同时进行实验方法研究,探讨奥沙利铂联合替吉奥胶囊抑制胃癌SGC-7901细胞的增殖及诱导细胞凋亡的作用。结果观察组总有效率为73.3%,对照组总有效率为50.0%,观察组明显高于对照组,有明显的统计学差异性(P<0.05)。毒副作用最常见的不良反应是胃肠道反应和造血、骨髓抑制等。体外实验中,奥沙利铂与替吉奥联合组24h细胞增殖抑制率高于单药组抑制率,差别有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥胶囊是有效、安全的化疗方案,值得推广。
Objective To investigate the clinical efficacy and safety of oxaliplatin combined with tigiao capsule in the treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer who were treated in Zhengzhou People’s Hospital from June 2010 to June 2012 were randomly divided into two groups. 30 cases in the observation group were treated with oxaliplatin combined with Gaga capsules, and 30 cases in the control group Treatment with cisplatin plus 5 fluorouracil plus leucovorin. At the same time, experimental methods were explored to explore the effect of oxaliplatin combined with tigiao capsule on the proliferation and apoptosis of gastric cancer SGC-7901 cells. Results The total effective rate was 73.3% in the observation group and 50.0% in the control group. The observation group was significantly higher than that of the control group, with significant statistical difference (P <0.05). The most common side effects of adverse reactions are gastrointestinal reactions and hematopoietic, bone marrow suppression. In vitro, the inhibitory rate of 24h proliferation of oxaliplatin and tegaserod combination group was higher than that of single drug group, the difference was statistically significant (P <0.05). Conclusion The combination of oxaliplatin and tioguan capsule is an effective and safe chemotherapy regimen, which is worth promoting.